BIO-RAD LABORATORIES-A (BIO)
US0905722072 - Common Stock
We assign a fundamental rating of 5 out of 10 to BIO. BIO was compared to 56 industry peers in the Life Sciences Tools & Services industry. BIO has an excellent financial health rating, but there are some minor concerns on its profitability. BIO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
BIO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
Each year in the past 5 years BIO had a positive operating cash flow.
1.2 Ratios
BIO has a better Return On Assets (-7.34%) than 60.71% of its industry peers.
BIO has a better Return On Equity (-10.40%) than 62.50% of its industry peers.
BIO has a better Return On Invested Capital (2.68%) than 66.07% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 9.98%.
The last Return On Invested Capital (2.68%) for BIO is above the 3 year average (2.68%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.34% | ||
| ROE | -10.4% | ||
| ROIC | 2.68% |
ROA(3y)-2.72%
ROA(5y)8.64%
ROE(3y)-4.64%
ROE(5y)11.05%
ROIC(3y)2.68%
ROIC(5y)2.71%
1.3 Margins
With a decent Operating Margin value of 13.30%, BIO is doing good in the industry, outperforming 73.21% of the companies in the same industry.
In the last couple of years the Operating Margin of BIO has grown nicely.
The Gross Margin of BIO (54.43%) is better than 66.07% of its industry peers.
In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.3% | ||
| PM (TTM) | N/A | ||
| GM | 54.43% |
OM growth 3Y-6.13%
OM growth 5Y9.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.75%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
BIO has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BIO has been reduced compared to 5 years ago.
The debt/assets ratio for BIO is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.47 indicates that BIO is not in any danger for bankruptcy at the moment.
The Altman-Z score of BIO (3.47) is better than 64.29% of its industry peers.
BIO has a debt to FCF ratio of 5.37. This is a neutral value as BIO would need 5.37 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 5.37, BIO is doing good in the industry, outperforming 67.86% of the companies in the same industry.
A Debt/Equity ratio of 0.16 indicates that BIO is not too dependend on debt financing.
BIO has a Debt to Equity ratio (0.16) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 5.37 | ||
| Altman-Z | 3.47 |
ROIC/WACC0.23
WACC11.42%
2.3 Liquidity
A Current Ratio of 6.14 indicates that BIO has no problem at all paying its short term obligations.
The Current ratio of BIO (6.14) is better than 80.36% of its industry peers.
BIO has a Quick Ratio of 4.52. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BIO (4.52) is better than 76.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.14 | ||
| Quick Ratio | 4.52 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased strongly by -12.27% in the last year.
The Earnings Per Share has been growing by 15.01% on average over the past years. This is quite good.
BIO shows a decrease in Revenue. In the last year, the revenue decreased by -5.15%.
The Revenue has been growing slightly by 3.13% on average over the past years.
EPS 1Y (TTM)-12.27%
EPS 3Y3.78%
EPS 5Y15.01%
EPS Q2Q%-13.73%
Revenue 1Y (TTM)-5.15%
Revenue growth 3Y1.62%
Revenue growth 5Y3.13%
Sales Q2Q%2.79%
3.2 Future
Based on estimates for the next years, BIO will show a small growth in Earnings Per Share. The EPS will grow by 2.80% on average per year.
Based on estimates for the next years, BIO will show a small growth in Revenue. The Revenue will grow by 2.38% on average per year.
EPS Next Y-11.83%
EPS Next 2Y-0.01%
EPS Next 3Y3.94%
EPS Next 5Y2.8%
Revenue Next Year-3.55%
Revenue Next 2Y-0.04%
Revenue Next 3Y1.54%
Revenue Next 5Y2.38%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BIO is valuated quite expensively with a Price/Earnings ratio of 31.16.
Based on the Price/Earnings ratio, BIO is valued a bit cheaper than 76.79% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.73, BIO is valued at the same level.
A Price/Forward Earnings ratio of 27.83 indicates a quite expensive valuation of BIO.
Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than 71.43% of the companies in the same industry.
BIO's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.16 | ||
| Fwd PE | 27.83 |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIO indicates a somewhat cheap valuation: BIO is cheaper than 71.43% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.99 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The decent profitability rating of BIO may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)2.08
EPS Next 2Y-0.01%
EPS Next 3Y3.94%
5. Dividend
5.1 Amount
No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIO-RAD LABORATORIES-A
NYSE:BIO (12/20/2024, 8:04:00 PM)
After market: 327.47 0 (0%)327.47
+1.53 (+0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.21%
Inst Owner Change0.45%
Ins Owners3.68%
Ins Owner Change0%
Market Cap9.17B
Analysts76.36
Price Target405.28 (23.76%)
Short Float %2.53%
Short Ratio2.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)62.45%
Min EPS beat(2)52.84%
Max EPS beat(2)72.05%
EPS beat(4)4
Avg EPS beat(4)34.88%
Min EPS beat(4)5.67%
Max EPS beat(4)72.05%
EPS beat(8)5
Avg EPS beat(8)15.22%
EPS beat(12)8
Avg EPS beat(12)15.76%
EPS beat(16)12
Avg EPS beat(16)22.75%
Revenue beat(2)1
Avg Revenue beat(2)0.15%
Min Revenue beat(2)-2.11%
Max Revenue beat(2)2.41%
Revenue beat(4)1
Avg Revenue beat(4)-0.89%
Min Revenue beat(4)-2.31%
Max Revenue beat(4)2.41%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)3
Avg Revenue beat(12)-1.7%
Revenue beat(16)7
Avg Revenue beat(16)1.64%
PT rev (1m)4.06%
PT rev (3m)10.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.83%
EPS NY rev (1m)0%
EPS NY rev (3m)7.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.16 | ||
| Fwd PE | 27.83 | ||
| P/S | 3.55 | ||
| P/FCF | 40.99 | ||
| P/OCF | 22.25 | ||
| P/B | 1.22 | ||
| P/tB | 1.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.51
EY3.21%
EPS(NY)11.77
Fwd EY3.59%
FCF(TTM)7.99
FCFY2.44%
OCF(TTM)14.72
OCFY4.49%
SpS92.15
BVpS267.42
TBVpS241.62
PEG (NY)N/A
PEG (5Y)2.08
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.34% | ||
| ROE | -10.4% | ||
| ROCE | 3.4% | ||
| ROIC | 2.68% | ||
| ROICexc | 3.2% | ||
| ROICexgc | 3.49% | ||
| OM | 13.3% | ||
| PM (TTM) | N/A | ||
| GM | 54.43% | ||
| FCFM | 8.67% |
ROA(3y)-2.72%
ROA(5y)8.64%
ROE(3y)-4.64%
ROE(5y)11.05%
ROIC(3y)2.68%
ROIC(5y)2.71%
ROICexc(3y)3.01%
ROICexc(5y)3.07%
ROICexgc(3y)3.2%
ROICexgc(5y)3.26%
ROCE(3y)3.39%
ROCE(5y)3.43%
ROICexcg growth 3Y-0.03%
ROICexcg growth 5Y-4.68%
ROICexc growth 3Y-1.05%
ROICexc growth 5Y-4.48%
OM growth 3Y-6.13%
OM growth 5Y9.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.75%
GM growth 5Y-0.04%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 5.37 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.3% | ||
| Interest Coverage | -7.35 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.14 | ||
| Quick Ratio | 4.52 | ||
| Altman-Z | 3.47 |
F-Score6
WACC11.42%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.27%
EPS 3Y3.78%
EPS 5Y15.01%
EPS Q2Q%-13.73%
EPS Next Y-11.83%
EPS Next 2Y-0.01%
EPS Next 3Y3.94%
EPS Next 5Y2.8%
Revenue 1Y (TTM)-5.15%
Revenue growth 3Y1.62%
Revenue growth 5Y3.13%
Sales Q2Q%2.79%
Revenue Next Year-3.55%
Revenue Next 2Y-0.04%
Revenue Next 3Y1.54%
Revenue Next 5Y2.38%
EBIT growth 1Y-12.83%
EBIT growth 3Y-4.61%
EBIT growth 5Y13.39%
EBIT Next Year24.12%
EBIT Next 3Y14.48%
EBIT Next 5Y11.63%
FCF growth 1Y47.57%
FCF growth 3Y-22.91%
FCF growth 5Y6.99%
OCF growth 1Y44.24%
OCF growth 3Y-13.78%
OCF growth 5Y5.6%